Understanding how the body rejects transplanted organs
CD11b: A Novel Alternate Receptor for CD154 during Alloimmunity
This research aims to uncover new ways the immune system causes organ rejection after a transplant, helping us find better treatments for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11049903 on NIH RePORTER |
What this research studies
When someone receives an organ transplant, their immune system can sometimes see the new organ as foreign and try to reject it. Doctors have tried blocking certain immune signals to prevent this, but some approaches work better than others. This project focuses on a specific immune signal called CD154 and a newly discovered partner, CD11b, to understand how they contribute to rejection. By learning more about these signals, we hope to develop more effective ways to protect transplanted organs.
Who could benefit from this research
Good fit: This foundational research is most relevant to patients who have received or will receive an organ transplant, particularly those who experience rejection.
Not a fit: Patients without organ transplants or conditions related to alloimmunity would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new and more effective medications to prevent organ rejection, improving the long-term health of transplant recipients.
How similar studies have performed: While blocking CD154 has shown promise in preclinical studies, its clinical translation has faced challenges, making this research into underlying mechanisms crucial.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Ford, Mandy L — Emory University
- Study coordinator: Ford, Mandy L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.